Cigarette Smoking and Adipose Tissue: The Emerging Role in Progression of Atherosclerosis

Mediators of Inflammation

Volumn 2017, Issue , 2017, Pages

  Wang, Zhiyan ^a   Wang, Di ^a   Wang, Yi ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CIGARETTE SMOKE; FATTY ACID BINDING PROTEIN 4; LEPTIN; NICOTINIC RECEPTOR; OMENTIN; RESISTIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; CIGARETTE SMOKING; ENDOCRINE FUNCTION; INFLAMMATION; LIPID METABOLISM; OBESITY; PATHOGENESIS; REVIEW; BLOOD; HUMAN; PHYSIOLOGY;

ADIPOCYTES; ADIPOSE TISSUE; ATHEROSCLEROSIS; CIGARETTE SMOKING; HUMANS; LEPTIN; LIPID METABOLISM; RECEPTORS, NICOTINIC;

EID: 85042616625     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2017/3102737     Document Type: Review

References (106)

1. M. Ezzati, S. J. Henley, M. J. Thun, and A. D. Lopez, "Role of smoking in global and regional cardiovascular mortality," Circulation, vol. 112, no. 4, pp. 489-497, 2005.
2. J. Dratva, N. Probst-Hensch, A. Schmidt-Trucksäss et al., "Atherogenesis in youth-early consequence of adolescent smoking," Atherosclerosis, vol. 230, no. 2, pp. 304-309, 2013.
3. M. M. Finucane, G. A. Stevens, M. J. Cowan et al., "National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants," The Lancet, vol. 377, no. 9765, pp. 557-567, 2011.
4. Q. Huynh, L. Blizzard, J. Sharman et al., "Relative contributions of adiposity in childhood and adulthood to vascular health of young adults," Atherosclerosis, vol. 228, no. 1, pp. 259-264, 2013.
5. D. M. Freedman, A. J. Sigurdson, P. Rajaraman, M. M. Doody, M. S. Linet, and E. Ron, "The mortality risk of smoking and obesity combined," American Journal of Preventive Medicine, vol. 31, no. 5, pp. 355-362, 2006.
6. A. Koster, M. F. Leitzmann, A. Schatzkin et al., "The combined relations of adiposity and smoking on mortality," American Journal of Clinical Nutrition, vol. 88, no. 5, pp. 1206-1212, 2008.
7. R. Chatkin, J. M. Chatkin, L. Spanemberg, D. Casagrande, M. Wagner, and C. Mottin, "Smoking is associated with more abdominal fat in morbidly obese patients," PLoS One, vol. 10, no. 5, article e0126146, 2015.
8. Y. Wu, P. Song, W. Zhang et al., "Activation of AMPKalpha2 in adipocytes is essential for nicotine-induced insulin resistance in vivo," Nature Medicine, vol. 21, no. 4, pp. 373-382, 2015.
9. H. Shimokata, D. C. Muller, and R. Andres, "Studies in the distribution of body fat. III. Effects of cigarette smoking," JAMA, vol. 261, no. 8, pp. 1169-1173, 1989.
10. M. Akbartabartoori, M. E. Lean, and C. R. Hankey, "Relationships between cigarette smoking, body size and body shape," International Journal of Obesity, vol. 29, no. 2, pp. 236-243, 2005.
11. I. Tabas, K. J. Williams, and J. Borén, "Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications," Circulation, vol. 116, no. 16, pp. 1832-1844, 2007.
12. A. J. Lusis, "Atherosclerosis," Nature, vol. 407, no. 6801, pp. 233-241, 2000.
13. Y. V. Bobryshev, "Monocyte recruitment and foam cell formation in atherosclerosis," Micron, vol. 37, no. 3, pp. 208-222, 2005.
14. K. A. Campbell, M. J. Lipinski, A. C. Doran, M. D. Skaflen, V. Fuster, and C. A. McNamara, "Lymphocytes and the adventitial immune response in atherosclerosis," Circulation Research, vol. 110, no. 6, pp. 889-900, 2012.
15. G. A. Payne, M. C. Kohr, and J. D. Tune, "Epicardial perivascular adipose tissue as a therapeutic target in obesity-related coronary artery disease," British Journal of Pharmacology, vol. 165, no. 3, pp. 659-669, 2012.
16. D. Préfontaine, A. Morin, C. Jumarie, and A. Porter, "In vitro bioactivity of combustion products from 12 tobacco constituents," Food and Chemical Toxicology, vol. 44, no. 5, pp. 724-738, 2006.
17. J. Lee and J. P. Cooke, "The role of nicotine in the pathogenesis of atherosclerosis," Atherosclerosis, vol. 215, no. 2, pp. 281-283, 2011.
18. R. D. Egleton, K. C. Brown, and P. Dasgupta, "Angiogenic activity of nicotinic acetylcholine receptors: implications in tobacco-related vascular diseases," Pharmacology &Therapeutics, vol. 121, no. 2, pp. 205-223, 2009.
19. H. Li, S. R. Srinivasan, W. Chen, J. H. Xu, S. Li, and G. S. Berenson, "Vascular abnormalities in asymptomatic, healthy young adult smokers without other major cardiovascular risk factors: the Bogalusa Heart Study," American Journal of Hypertension, vol. 18, no. 3, pp. 319-324, 2005.
20. H. L. Luo, W. J. Zang, J. Lu, X. J. Yu, Y. X. Lin, and Y. X. Cao, "The protective effect of captopril on nicotine-induced endothelial dysfunction in rat," Basic &Clinical Pharmacology &Toxicology, vol. 99, no. 3, pp. 237-245, 2006.
21. C. Heeschen, M. Weis, and J. P. Cooke, "Nicotine promotes arteriogenesis," Journal of the American College of Cardiology, vol. 41, no. 3, pp. 489-496, 2003.
22. M. S. Zhou, K. Chadipiralla, A. J. Mendez et al., "Nicotine potentiates proatherogenic effects of oxLDL by stimulating and upregulating macrophage CD36 signaling," American Journal of Physiology: Heart and Circulatory Physiology, vol. 305, no. 4, pp. H563-H574, 2013.
23. P. P. Lau, L. Li, A. J. Merched, A. L. Zhang, K. W. Ko, and L. Chan, "Nicotine induces proinflammatory responses in macrophages and the aorta leading to acceleration of atherosclerosis in low-density lipoprotein receptor-/-mice," Arteriosclerosis Thrombosis &Vascular Biology, vol. 26, no. 1, pp. 143-149, 2006.
24. A. Cucina, P. Sapienza, V. Corvino et al., "Nicotine induces platelet-derived growth factor release and cytoskeletal alteration in aortic smooth muscle cells," Surgery, vol. 127, no. 1, pp. 72-78, 2000.
25. A. Csordas and D. Bernhard, "The biology behind the atherothrombotic effects of cigarette smoke," Nature Reviews Cardiology, vol. 10, no. 4, pp. 219-230, 2013.
26. S. Iwano, M. Nukaya, T. Saito, F. Asanuma, and T. Kamataki, "A possible mechanism for atherosclerosis induced by polycyclic aromatic hydrocarbons," Biochemical and Biophysical Research Communications, vol. 335, no. 1, pp. 220-226, 2005.
27. G. Siasos, V. Tsigkou, E. Kokkou et al., "Smoking and atherosclerosis: mechanisms of disease and new therapeutic approaches," Current Medicinal Chemistry, vol. 21, no. 34, pp. 3936-3948, 2014.
28. D. C. Lau, B. Dhillon, H. Yan, P. E. Szmitko, and S. Verma, "Adipokines: molecular links between obesity and atheroslcerosis," American Journal of Physiology Heart &Circulatory Physiology, vol. 288, no. 5, pp. H2031-H2041, 2005.
29. J. J. Fuster, N. Ouchi, N. Gokce, and K. Walsh, "Obesityinduced changes in adipose tissue microenvironment and their impact on cardiovascular disease," Circulation Research, vol. 118, no. 11, pp. 1786-1807, 2016.
30. B. Klop, J. W. Elte, and M. C. Cabezas, "Dyslipidemia in obesity: mechanisms and potential targets," Nutrients, vol. 5, no. 4, pp. 1218-1240, 2013.
31. Y. Zhang, R. Proenca, M. Maffei, M. Barone, L. Leopold, and J. M. Friedman, "Positional cloning of the mouse obese gene and its human homologue," Nature, vol. 372, no. 6505, pp. 425-432, 1994.
32. M. W. Rajala, Y. Qi, H. R. Patel et al., "Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting," Diabetes, vol. 53, no. 7, pp. 1671-1679, 2004.
33. G. S. Hotamisligil, N. S. Shargill, and B. M. Spiegelman, "Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance," Science, vol. 259, no. 5091, pp. 87-91, 1993.
34. Y. Arita, S. Kihara, N. Ouchi et al., "Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity," Biochemical &Biophysical Research Communications, vol. 257, no. 1, pp. 79-83, 1999.
35. D. S. B. Cm, R. Z. Yang, M. J. Lee et al., "Omentin plasma levels and gene expression are decreased in obesity," Diabetes, vol. 56, no. 6, pp. 1655-1661, 2007.
36. K. H. Cheng, C. S. Chu, K. T. Lee et al., "Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease," International Journal of Obesity, vol. 32, no. 2, pp. 268-274, 2008.
37. Y. H. Jin, Y. J. Park, M. Ham, and J. B. Kim, "Crosstalk between adipocytes and immune cells in adipose tissue inflammation and metabolic dysregulation in obesity," Molecules and Cells, vol. 37, no. 5, pp. 365-371, 2014.
38. Y. J. Gao, "Dual modulation of vascular function by perivascular adipose tissue and its potential correlation with adiposity/lipoatrophy-related vascular dysfunction," Current Pharmaceutical Design, vol. 13, no. 21, pp. 2185-2192, 2007.
39. K. Rittig, J. H. Dolderer, B. Balletshofer et al., "The secretion pattern of perivascular fat cells is different from that of subcutaneous and visceral fat cells," Diabetologia, vol. 55, no. 5, pp. 1514-1525, 2012.
40. C. Gotti, E. Carbonnelle, M. Moretti, R. Zwart, and F. Clementi, "Drugs selective for nicotinic receptor subtypes: a real possibility or a dream?," Behavioural Brain Research, vol. 113, no. 1-2, pp. 183-192, 2000.
41. R. Cancello, A. Zulian, S. Maestrini et al., "The nicotinic acetylcholine receptor α7 in subcutaneous mature adipocytes: downregulation in human obesity and modulation by dietinduced weight loss," International Journal of Obesity, vol. 36, no. 12, pp. 1552-1557, 2012.
42. K. Andersson and P. Arner, "Systemic nicotine stimulates human adipose tissue lipolysis through local cholinergic and catecholaminergic receptors," International Journal of Obesity, vol. 25, no. 8, pp. 1225-1232, 2001.
43. V. Narayanaswami, S. S. Somkuwar, D. B. Horton, L. A. Cassis, and L. P. Dwoskin, "Angiotensin AT1 and AT2 receptor antagonists modulate nicotine-evoked[3H]dopamine and [3H]norepinephrine release," Biochemical Pharmacology, vol. 86, no. 5, pp. 656-665, 2013.
44. L. Azam and J. M. McIntosh, "Characterization of nicotinic acetylcholine receptors that modulate nicotineevoked [3H]norepinephrine release from mouse hippocampal synaptosomes," Molecular Pharmacology, vol. 70, no. 3, pp. 967-976, 2006.
45. H. M. Schuller, P. K. Tithof, M. Williams, and H. Plummer 3rd, "The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a β-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via β-adrenergic receptor-mediated release of arachidonic acid," Cancer Research, vol. 59, no. 18, p. 4510, 1999.
46. M. Alexandre, A. K. Uduman, S. Minervini et al., "Tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone initiates and enhances pancreatitis responses," American Journal of Physiology Gastrointestinal and Liver Physiology, vol. 303, no. 6, pp. G696-G704, 2012.
47. P. K. Tithof, M. Elgayyar, H. M. Schuller, M. Barnhill, and R. Andrews, "4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone, a nicotine derivative, induces apoptosis of endothelial cells," American Journal of Physiology: Heart and Circulatory Physiology, vol. 281, no. 5, pp. H1946-H1954, 2001.
48. W. Cao, A. V. Medvedev, K. W. Daniel, and S. Collins, "β-Adrenergic activation of p38 MAP kinase in adipocytes: cAMP induction of the uncoupling protein 1 (UCP1) gene requires p38 MAP kinase," Journal of Biological Chemistry, vol. 276, no. 29, pp. 27077-27082, 2001.
49. M. Fasshauer, J. Klein, S. Neumann, M. Eszlinger, and R. Paschke, "Adiponectin gene expression is inhibited by β-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes," FEBS Letters, vol. 507, no. 2, pp. 142-146, 2001.
50. A. Chiolero, D. Faeh, F. Paccaud, and J. Cornuz, "Consequences of smoking for body weight, body fat distribution, and insulin resistance," The American Journal of Clinical Nutrition, vol. 87, no. 4, pp. 801-809, 2008.
51. E. de Oliveira, E. G. Moura, A. P. Santos-Silva et al., "Neonatal nicotine exposure causes insulin and leptin resistance and inhibits hypothalamic leptin signaling in adult rat offspring," Journal of Endocrinology, vol. 206, no. 1, pp. 55-63, 2010.
52. E. Somm, V. M. Schwitzgebel, D. M. Vauthay et al., "Prenatal nicotine exposure alters early pancreatic islet and adipose tissue development with consequences on the control of body weight and glucose metabolism later in life," Endocrinology, vol. 149, no. 12, pp. 6289-6299, 2008.
53. T. Yamauchi, J. Kamon, H. Waki et al., "The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ (PPARγ) deficiency and PPARγ agonist improve insulin resistance," Journal of Biological Chemistry, vol. 276, no. 44, pp. 41245-41254, 2001.
54. P. D. G. Miles, Y. Barak, W. He, R. M. Evans, and J. M. Olefsky, "Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency," Journal of Clinical Investigation, vol. 105, no. 3, pp. 287-292, 2000.
55. D. Ren, T. N. Collingwood, E. J. Rebar, A. P. Wolffe, and H. S. Camp, "PPARγ knockdown by engineered transcription factors: exogenous PPARγ2 but not PPARγ1 reactivates adipogenesis," Genes &Development, vol. 16, no. 1, pp. 27-32, 2002.
56. Z. An, H. Wang, P. Song, M. Zhang, X. Geng, and M. H. Zou, "Nicotine-induced activation of AMP-activated protein kinase inhibits fatty acid synthase in 3T3L1 adipocytes: a role for oxidant stress," Journal of Biological Chemistry, vol. 282, no. 37, pp. 26793-26801, 2007.
57. M. Itoh, T. Tsuji, H. Nakamura et al., "Systemic effects of acute cigarette smoke exposure in mice," Inhalation Toxicology, vol. 26, no. 8, pp. 464-473, 2014.
58. H. Lee, Y. J. Lee, H. Choi, E. H. Ko, and J. Kim, "Reactive oxygen species facilitate adipocyte differentiation by accelerating mitotic clonal expansion," Journal of Biological Chemistry, vol. 284, no. 16, pp. 10601-10609, 2009.
59. P. A. Hosick, A. A. AlAmodi, M. V. Storm et al., "Chronic carbon monoxide treatment attenuates development of obesity and remodels adipocytes in mice fed a high-fat diet," International Journal of Obesity, vol. 38, no. 1, pp. 132-139, 2014.
60. P. Irigaray, S. Lacomme, L. Mejean, and D. Belpomme, "Ex vivo study of incorporation into adipocytes and lipolysis-inhibition effect of polycyclic aromatic hydrocarbons," Toxicology Letters, vol. 187, no. 1, pp. 35-39, 2009.
61. J. H. Kim, K. Yamaguchi, S. H. Lee et al., "Evaluation of polycyclic aromatic hydrocarbons in the activation of early growth response-1 and peroxisome proliferator activated receptors," Toxicological Sciences, vol. 85, no. 1, pp. 585-593, 2005.
62. H. E. Bays, "Adiposopathy is "sick fat" a cardiovascular disease?," Journal of the American College of Cardiology, vol. 57, no. 25, pp. 2461-2473, 2011.
63. D. Langin, "Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome," Pharmacological Research, vol. 53, no. 6, pp. 482-491, 2006.
64. Y. Iwashima, T. Katsuya, K. Ishikawa et al., "Association of hypoadiponectinemia with smoking habit in men," Hypertension, vol. 45, no. 6, pp. 1094-1100, 2005.
65. S. Bergmann and R. Siekmeier, "Influence of smoking and body weight on adipokines in middle aged women," European Journal of Medical Research, vol. 14, Supplement 4, pp. 21-26, 2009.
66. K. Parisi, L. Tzanoumis, and A. Kafouri, "Smoking cessation increases serum adiponectin levels in an apparently healthy Greek population," Atherosclerosis, vol. 205, no. 2, pp. 632-636, 2009.
67. M. Li, C. Li, Y. Liu et al., "Decreased secretion of adiponectin through its intracellular accumulation in adipose tissue during tobacco smoke exposure," Nutrition &Metabolism, vol. 12, no. 1, p. 15, 2014.
68. K. Merz-Atalik, "Tnfα, Cox2 and AdipoQ adipokine gene expression levels are modulated in murine adipose tissues by both nicotine and nACh receptors containing the β2 subunit," Molecular Genetics &Metabolism, vol. 107, no. 3, pp. 561-570, 2012.
69. M. L. Delporte, T. Funahashi, M. Takahashi, Y. Matsuzawa, and S. M. Brichard, "Pre-and post-translational negative effect of β-adrenoceptor agonists on adiponectin secretion: in vitro and in vivo studies," Biochemical Journal, vol. 367, Part 3, pp. 677-685, 2002.
70. N. Maeda, I. Shimomura, K. Kishida et al., "Diet-induced insulin resistance in mice lacking adiponection/ACRP30," Nature Medicine, vol. 8, no. 7, pp. 731-737, 2002.
71. L. Mach, H. Bedanova, M. Soucek, M. Karpisek, P. Nemec, and M. Orban, "Tobacco smoking and cytokine levels in human epicardial adipose tissue: impact of smoking cessation," Atherosclerosis, vol. 255, pp. 37-42, 2016.
72. M. Ryden, A. Dicker, V. van Harmelen et al., "Mapping of early signaling events in tumor necrosis factor-α-mediated lipolysis in human fat cells," Journal of Biological Chemistry, vol. 277, no. 2, pp. 1085-1091, 2002.
73. R. H. Liu, M. Mizuta, and S. Matsukura, "The expression and functional role of nicotinic acetylcholine receptors in rat adipocytes," The Journal of Pharmacology and Experimental Therapeutics, vol. 310, no. 1, pp. 52-58, 2004.
74. J. L. Nobre, P. C. Lisboa, A. P. Santos-Silva et al., "Calcium supplementation reverts central adiposity, leptin, and insulin resistance in adult offspring programed by neonatal nicotine exposure," Journal of Endocrinology, vol. 210, no. 3, pp. 349-359, 2011.
75. G. Targher, L. Zenari, G. Faccini, G. Falezza, M. Muggeo, and G. Zoppini, "Serum leptin concentrations in young smokers with type 1 diabetes," Diabetes Care, vol. 24, no. 4, pp. 793-794, 2001.
76. J. E. Reseland, H. H. Mundal, K. Hollung et al., "Cigarette smoking may reduce plasma leptin concentration via catecholamines," Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 73, no. 1, pp. 43-49, 2005.
77. K. A. Perkins and C. Fonte, "Effects of smoking status and smoking cessation on leptin levels," Nicotine &Tobacco Research, vol. 4, no. 4, pp. 459-466, 2002.
78. C. Rossi, E. Santini, M. Chiarugi et al., "The complex P2X7 receptor/inflammasome in perivascular fat tissue of heavy smokers," European Journal of Clinical Investigation, vol. 44, no. 3, pp. 295-302, 2013.
79. K. Karimi, H. Sarir, E. Mortaz et al., "Toll-like receptor-4 mediates cigarette smoke-induced cytokine production by human macrophages," Respiratory Research, vol. 7, no. 1, p. 66, 2006.
80. K. Ohashi, J. L. Parker, N. Ouchi et al., "Adiponectin promotes macrophage polarization toward an antiinflammatory phenotype," Journal of Biological Chemistry, vol. 285, no. 9, pp. 6153-6160, 2010.
81. G. M. Lord, G. Matarese, J. K. Howard, R. J. Baker, S. R. Bloom, and R. I. Lechler, "Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression," Nature, vol. 394, no. 6696, pp. 897-901, 1998.
82. K. Rahmouni, D. A. Morgan, G. M. Morgan, A. L. Mark, and W. G. Haynes, "Role of selective leptin resistance in dietinduced obesity hypertension," Diabetes, vol. 54, no. 7, pp. 2012-2018, 2005.
83. C. L. Yun and J. R. Zierath, "AMP-activated protein kinase signaling in metabolic regulation," Journal of Clinical Investigation, vol. 116, no. 7, pp. 1776-1783, 2006.
84. A. Bouloumié, T. Marumo, M. Lafontan, and R. Busse, "Leptin induces oxidative stress in human endothelial cells," Faseb Journal, vol. 13, no. 13, pp. 1231-1238, 1999.
85. S. Hongo, T. Watanabe, S. Arita et al., "Leptin modulates ACAT1 expression and cholesterol efflux from human macrophages," American Journal of Physiology Endocrinology &Metabolism, vol. 297, no. 2, pp. E474-E482, 2009.
86. L. O'Rourke, L. M. Grønning, S. J. Yeaman, and P. R. Shepherd, "Glucose-dependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin," Journal of Biological Chemistry, vol. 277, no. 45, pp. 42557-42562, 2002.
87. L. Li, J. C. Mamputu, N. Wiernsperger, and G. Renier, "Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin," Diabetes, vol. 54, no. 7, pp. 2227-2234, 2005.
88. N. Kiguchi, T. Maeda, Y. Kobayashi, Y. Fukazawa, and S. Kishioka, "Leptin enhances CC-chemokine ligand expression in cultured murine macrophage," Biochemical &Biophysical Research Communications, vol. 384, no. 3, pp. 311-315, 2009.
89. T. Kadowaki and T. Yamauchi, "Adiponectin and adiponectin receptors," Endocrine Reviews, vol. 26, no. 3, pp. 439-451, 2005.
90. H. Kobayashi, N. Ouchi, S. Kihara et al., "Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin," Circulation Research, vol. 94, no. 4, pp. e27-e31, 2004.
91. N. Ouchi, S. Kihara, Y. Arita et al., "Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NFkB signaling through a cAMP-dependent pathway," Circulation, vol. 102, no. 11, pp. 1296-1301, 2000.
92. N. Ouchi, S. Kihara, Y. Arita et al., "Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages," Circulation, vol. 103, no. 8, pp. 1057-1063, 2001.
93. Y. Arita, S. Kihara, N. Ouchi et al., "Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factorinduced common postreceptor signal in vascular smooth muscle cell," Circulation, vol. 105, no. 24, pp. 2893-2898, 2002.
94. G. S. Hotamisligil, A. Budavari, D. Murray, and B. M. Spiegelman, "Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha," Journal of Clinical Investigation, vol. 94, no. 4, pp. 1543-1549, 1994.
95. P. Kleinbongard, G. Heusch, and R. Schulz, "TNFα in atherosclerosis, myocardial ischemia/reperfusion and heart failure," Pharmacology &Therapeutics, vol. 127, no. 3, pp. 295-314, 2010.
96. J. J. Boyle, P. L. Weissberg, and M. R. Bennett, "Tumor necrosis factor-α promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms," Arteriosclerosis Thrombosis &Vascular Biology, vol. 23, no. 9, pp. 1553-1558, 2003.
97. H. Yamawaki, J. Kuramoto, S. Kameshima, T. Usui, M. Okada, and Y. Hara, "Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells," Biochemical and Biophysical Research Communications, vol. 408, no. 2, pp. 339-343, 2011.
98. S. Maruyama, R. Shibata, R. Kikuchi et al., "Fat-derived factor omentin stimulates endothelial cell function and ischemia-induced revascularization via endothelial nitric oxide synthase-dependent mechanism," Journal of Biological Chemistry, vol. 287, no. 1, pp. 408-417, 2012.
99. J. M. Northcott, A. Yeganeh, C. G. Taylor, P. Zahradka, and J. T. Wigle, "Adipokines and the cardiovascular system: mechanisms mediating health and disease," Canadian Journal of Physiology and Pharmacology, vol. 90, no. 8, pp. 1029-1059, 2012.
100. H. Yamawaki, N. Tsubaki, M. Mukohda, M. Okada, and Y. Hara, "Omentin, a novel adipokine, induces vasodilation in rat isolated blood vessels," Biochemical and Biophysical Research Communications, vol. 393, no. 4, pp. 668-672, 2010.
101. M. S. Burnett, C. W. Lee, T. D. Kinnaird et al., "The potential role of resistin in atherogenesis," Atherosclerosis, vol. 182, no. 2, pp. 241-248, 2005.
102. D. Kawanami, K. Maemura, N. Takeda et al., "Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokineendothelial cell interactions," Biochemical and Biophysical Research Communications, vol. 314, no. 2, pp. 415-419, 2004.
103. T. S. Lee, C. Y. Lin, J. Y. Tsai et al., "Resistin increases lipid accumulation by affecting class A scavenger receptor, CD36 and ATP-binding cassette transporter-A1 in macrophages," Life Sciences, vol. 84, no. 3-4, pp. 97-104, 2009.
104. J. B. Boord, K. Maeda, L. Makowski et al., "Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice," Circulation, vol. 110, no. 11, pp. 1492-1498, 2004.
105. L. Makowski, J. B. Boord, K. Maeda et al., "Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis," Nature Medicine, vol. 7, no. 6, pp. 699-705, 2001.
106. R. Hart and D. R. Greaves, "Chemerin contributes to inflammation by promoting macrophage adhesion to VCAM-1 and fibronectin through clustering of VLA-4 and VLA-5," The Journal of Immunology, vol. 185, no. 6, pp. 3728-3739, 2010.